| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01590823 | Blood Coagulation Disorders | Drug: Dabigatran Etexilate 110 mg | Nova Scotia Health Authority|Capital Health, Canada|Dalhousie University|Universit de Montral | Phase 1 | 2012-07-01 | 2012-10-31 |
| NCT02426229 | Scleroderma|Interstitial Lung Disease | Drug: dabigatran etexilate | Medical University of South Carolina|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 1 | 2016-02-01 | 2017-03-22 |
| NCT01976507 | Atrial Fibrillation|Atrial Flutter | Drug: dabigatran etexilate mesylate | Vanderbilt University Medical Center|Boehringer Ingelheim | Phase 4 | 2013-10-01 | 2017-02-21 |
| NCT02173717 | Healthy | Drug: Dabigatran etexilate|Drug: Rifampicin | Boehringer Ingelheim | Phase 1 | 2009-06-01 | 2014-06-24 |
| NCT01385683 | Healthy | Drug: Dabigatran then dabigatran and clarithromycin|Drug: Clarithromycin and dabigatran then dabigatran | Centre Hospitalier Universitaire de Saint Etienne|Groupe de Recherche sur la Thrombose | Phase 1 | 2011-06-01 | 2012-03-21 |
| NCT01546883 | Atrial Fibrillation | Drug: Dabigatran etexilate (Pradaxa) | University of Utah | Phase 4 | 2012-02-01 | 2015-09-10 |
| NCT01769703 | Transient Ischemic Attack|Minor Ischemic Stroke | Drug: Dabigatran 110/150 mg BID | University of Alberta | Phase 2 | 2012-02-01 | 2014-10-29 |
| NCT01852162 | Coronary Artery Disease | Drug: Dabigatran|Drug: Placebo | University of Florida | | 2012-02-01 | 2015-03-10 |
| NCT02389582 | Coronary Disease | Drug: Dabigatran|Drug: Enoxaparin | University of Sao Paulo General Hospital|Fundao de Amparo Pesquisa do Estado de So Paulo | Phase 4 | 2014-05-01 | 2016-04-28 |
| NCT02256683 | (Atrial Fibrillation) or (Atrial Flutter)|Thrombosis of Left Atrial Appendage | Drug: Dabigatran etexilate|Drug: Phenprocoumon | Johannes Gutenberg University Mainz|Boehringer Ingelheim|German Atrial Fibrillation Network | Phase 4 | 2014-07-01 | 2016-02-26 |
| NCT01290757 | Healthy | Drug: Dabigatran etexilate|Drug: Dabigatran etexilate | Boehringer Ingelheim | Phase 1 | 2011-01-01 | 2014-05-08 |
| NCT02596555 | Pulmonary Embolism | Drug: Dabigatran | Prof. Stavros Konstantinides, MD|European Georges Pompidou Hospital|Johannes Gutenberg University Mainz | Phase 4 | 2016-01-01 | 2016-04-26 |
| NCT01711853 | Renal Insufficiency, Chronic | Drug: Dabigatran Etexilate | Boehringer Ingelheim | Phase 1 | 2012-10-01 | 2015-01-09 |
| NCT02223260 | Venous Thromboembolism | Drug: dabigatran | Boehringer Ingelheim | Phase 2 | 2014-09-01 | 2016-07-28 |
| NCT02331602 | Atrial Fibrillation | Drug: Rivaroxaban|Drug: Dabigatran | Yokohama City University Medical Center|Yokohama City University | Phase 4 | 2013-07-01 | 2015-08-04 |
| NCT02102633 | Healthy | Drug: Dabigatran|Drug: Bosutinib|Drug: Dabigatran | Pfizer | Phase 1 | 2014-05-01 | 2014-06-23 |
| NCT00808067 | Atrial Fibrillation | Drug: dabigatran dose 1|Drug: dabigatran dose 2 | Boehringer Ingelheim | Phase 3 | 2008-11-01 | 2014-06-03 |
| NCT01868243 | Primary Disease | Drug: Dabigatran|Drug: Warfarin | Hospital Ana Nery | Phase 2|Phase 3 | 2013-08-01 | 2015-09-14 |
| NCT02044367 | Healthy | Drug: Dabigatran etexilate|Drug: Dabigatran etexilate|Drug: Dabigatran etexilate | Boehringer Ingelheim | Phase 1 | 2014-01-01 | 2015-05-01 |
| NCT00844415 | Venous Thromboembolism | Drug: dabigatran etexilate | Boehringer Ingelheim | Phase 2 | 2009-06-01 | 2014-06-03 |
| NCT02170675 | Healthy | Drug: Dabigatran etexilate|Drug: Ketoconazole | Boehringer Ingelheim | Phase 1 | 2009-06-01 | 2014-06-20 |
| NCT01083732 | Venous Thromboembolism | Drug: dabigatran etexilate | Boehringer Ingelheim | Phase 2 | 2010-03-01 | 2016-11-02 |
| NCT01468155 | Atrial Fibrillation | Drug: dabigatran | Allan Skanes|Boehringer Ingelheim|Lawson Health Research Institute | Phase 4 | 2011-11-01 | 2012-10-16 |
